TLDR
- DTIL jumps as EASL data boost confidence in HBV gene editing results.
- Precision BioSciences gains after PBGENE-HBV shows cccDNA activity.
- DTIL stock rises pre-market on fresh hepatitis B gene editing data.
- PBGENE-HBV results lift DTIL as EASL data show clinical progress.
- Precision BioSciences climbs as HBV therapy data fuel market interest.
Precision BioSciences (DTIL) shares gained fresh market attention after new hepatitis B data strengthened confidence in its ARCUS gene editing platform. DTIL closed at $7.58, up 4.84%, then rose pre-market to $8.34, up 10.03%. The stock also showed early strength near $8.55 as traders reacted to late-breaking EASL 2026 results.
Precision BioSciences, Inc., DTIL
DTIL Stock Rises After Strong EASL Data
Precision BioSciences presented new clinical findings from its ELIMINATE-B study at the EASL Annual Congress 2026. The study evaluates PBGENE-HBV, an in vivo gene editing therapy for chronic hepatitis B. The company said the data showed the first clinical evidence of cccDNA elimination and inactivation in treated patients.
The chart showed early strength near $8.55 as the announcement drew strong attention. The move reflected a clear reaction to data that addressed a core challenge in hepatitis B treatment. However, the company still continues clinical development as it expands enrollment across study cohorts.
PBGENE-HBV Shows Direct cccDNA Targeting
Precision BioSciences uses its proprietary ARCUS platform to develop gene editing therapies for high-need diseases. PBGENE-HBV targets chronic hepatitis B by aiming at the root source of viral replication. The company designed the therapy to eliminate and inactivate cccDNA inside liver cells.
As of May 4, 2026, researchers had administered 38 doses to 16 patients across five cohorts. The new biopsy results showed a 1-log reduction in cccDNA transcripts after two doses. The finding came at the 0.4 mg/kg dose level, using long-read transcript sequencing.
The company also reported further editing of the remaining cccDNA after the elimination process. These edits targeted polymerase function and aimed to stop viral replication. Additionally, repeat dosing showed cumulative activity, with editing reaching 80% of remaining cccDNA after three administrations.
Biomarker Results Add Clinical Context
The EASL data also highlighted pgRNA as a key blood biomarker for PBGENE-HBV activity. The company said pgRNA comes only from cccDNA and supports HBV DNA production. Therefore, durable pgRNA loss may help assess cccDNA editing inside the liver.
Precision BioSciences reported durable loss of detectable blood pgRNA in all six patients with measurable levels before treatment. The result appeared across four dosing cohorts and supported a broad therapeutic window. Post-treatment liver biopsy data matched the blood biomarker findings.
The company also reported HBsAg declines in all 15 evaluated patients. These declines appeared across dose levels, geographies, baseline HBsAg levels, and HBV genotypes. In the longest-treated patient, HBsAg decline lasted more than one year after the first dose.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
